CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people

MI (Maren) Blonk; Nathalie van der Velde; Patricia Bemt; Ron van Schaik; T.J.M. van der Cammen

doi:10.1007/s11096-009-9349-1

CYP2D64, CYP3A53 and ABCB1 3435T polymorphisms and drug-related falls in elderly people

MI (Maren) Blonk, Nathalie van der Velde, Patricia Bemt, Ron van Schaik, T.J.M. van der Cammen

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

Objective The objective of this study is to investigate the association between CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls. Method Multivariate logistic regression was performed in an existing database in order to study the association between falls history and CYP2D6*4, CYP3A5*3, ABCB1 3435T polymorphisms in patients using fall-risk-increasing CYP2D6, CYP3A5 and P-glycoprotein (gene product of ABCB1) substrates. Results No statistically significant increased fall risk was found in 'poor metabolizers' compared to 'extensive' and 'intermediate metabolizers' using fall-risk-increasing CYP2D6 substrates (Odds ratio (OR) = 2.2; 95% confidence interval (CI) 0.2-25.0), CYP3A5 substrates (OR = 0.9; 95% CI 0.2-3.3) and P-glycoprotein substrates (OR = 2.1; 95% CI 0.2-17.2). Conclusion The hypothesis that 'poor metabolizers' have an increased fall risk was not confirmed. A larger study population is needed to confirm the potential association that was seen between CYP2D6*4 and ABCB1 3435T polymorphisms and drug-related falls.

Original language	Undefined/Unknown
Pages (from-to)	26-29
Number of pages	4
Journal	Pharmacy World & Science
Volume	32
Issue number	1
DOIs	https://doi.org/10.1007/s11096-009-9349-1
Publication status	Published - 2010

Research programs

EMC COEUR-09
EMC MM-01-25-01
EMC OR-01-34-01
EMC OR-01-39-08

Access to Document

10.1007/s11096-009-9349-1

http://hdl.handle.net/1765/28122

Cite this

@article{ed77b45dda894b0fb0d211b5add2c5f1,

title = "CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people",

abstract = "Objective The objective of this study is to investigate the association between CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls. Method Multivariate logistic regression was performed in an existing database in order to study the association between falls history and CYP2D6*4, CYP3A5*3, ABCB1 3435T polymorphisms in patients using fall-risk-increasing CYP2D6, CYP3A5 and P-glycoprotein (gene product of ABCB1) substrates. Results No statistically significant increased fall risk was found in 'poor metabolizers' compared to 'extensive' and 'intermediate metabolizers' using fall-risk-increasing CYP2D6 substrates (Odds ratio (OR) = 2.2; 95% confidence interval (CI) 0.2-25.0), CYP3A5 substrates (OR = 0.9; 95% CI 0.2-3.3) and P-glycoprotein substrates (OR = 2.1; 95% CI 0.2-17.2). Conclusion The hypothesis that 'poor metabolizers' have an increased fall risk was not confirmed. A larger study population is needed to confirm the potential association that was seen between CYP2D6*4 and ABCB1 3435T polymorphisms and drug-related falls.",

author = "Blonk, {MI (Maren)} and {van der Velde}, Nathalie and Patricia Bemt and {van Schaik}, Ron and {van der Cammen}, T.J.M.",

year = "2010",

doi = "10.1007/s11096-009-9349-1",

language = "Undefined/Unknown",

volume = "32",

pages = "26--29",

journal = "Pharmacy World & Science",

issn = "0928-1231",

publisher = "Springer Science+Business Media",

number = "1",

}

TY - JOUR

T1 - CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people

AU - Blonk, MI (Maren)

AU - van der Velde, Nathalie

AU - Bemt, Patricia

AU - van Schaik, Ron

AU - van der Cammen, T.J.M.

PY - 2010

Y1 - 2010

N2 - Objective The objective of this study is to investigate the association between CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls. Method Multivariate logistic regression was performed in an existing database in order to study the association between falls history and CYP2D6*4, CYP3A5*3, ABCB1 3435T polymorphisms in patients using fall-risk-increasing CYP2D6, CYP3A5 and P-glycoprotein (gene product of ABCB1) substrates. Results No statistically significant increased fall risk was found in 'poor metabolizers' compared to 'extensive' and 'intermediate metabolizers' using fall-risk-increasing CYP2D6 substrates (Odds ratio (OR) = 2.2; 95% confidence interval (CI) 0.2-25.0), CYP3A5 substrates (OR = 0.9; 95% CI 0.2-3.3) and P-glycoprotein substrates (OR = 2.1; 95% CI 0.2-17.2). Conclusion The hypothesis that 'poor metabolizers' have an increased fall risk was not confirmed. A larger study population is needed to confirm the potential association that was seen between CYP2D6*4 and ABCB1 3435T polymorphisms and drug-related falls.

AB - Objective The objective of this study is to investigate the association between CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls. Method Multivariate logistic regression was performed in an existing database in order to study the association between falls history and CYP2D6*4, CYP3A5*3, ABCB1 3435T polymorphisms in patients using fall-risk-increasing CYP2D6, CYP3A5 and P-glycoprotein (gene product of ABCB1) substrates. Results No statistically significant increased fall risk was found in 'poor metabolizers' compared to 'extensive' and 'intermediate metabolizers' using fall-risk-increasing CYP2D6 substrates (Odds ratio (OR) = 2.2; 95% confidence interval (CI) 0.2-25.0), CYP3A5 substrates (OR = 0.9; 95% CI 0.2-3.3) and P-glycoprotein substrates (OR = 2.1; 95% CI 0.2-17.2). Conclusion The hypothesis that 'poor metabolizers' have an increased fall risk was not confirmed. A larger study population is needed to confirm the potential association that was seen between CYP2D6*4 and ABCB1 3435T polymorphisms and drug-related falls.

U2 - 10.1007/s11096-009-9349-1

DO - 10.1007/s11096-009-9349-1

M3 - Article

SN - 0928-1231

VL - 32

SP - 26

EP - 29

JO - Pharmacy World & Science

JF - Pharmacy World & Science

IS - 1

ER -